Intrabiliary Radiofrequency Heating-Enhanced Direct Intratumoral GFP/HSV-TK Gene Therapy of Cholangiocarcinoma: A Preclinical Study on Mice and Pigs

F Zhang,Y JIN,S Jingjing,J Gao,X Yang

DOI: https://doi.org/10.1016/j.jvir.2016.12.850

IF: 3.682

2017-01-01

Journal of Vascular and Interventional Radiology

Abstract:To develop a new interventional oncology technique, "radiofrequency hyperthermia (RFH)-enhanced herpes simplex virus thymidine kinase (GFP/HSV-TK)/ganciclovir (GCV) gene therapy of cholangiocarcinoma." Luciferase/mCherry-labeled cholangiocarcinoma cells and 24 mice with subcutaneously implanted cholangiocarcinoma cells were treated by: (i) a combination of green fluorescent protein (GFP)/HSV-TK/plasmid gene transfection followed by RFH and ganciclovir exposure; (ii) gene therapy alone; (iii) RFH alone; and (iv) phosphate-buffered saline (PBS) to serve as a control (6 mice per group). Cell viabilities were quantified by MTS assay. Bioluminescent optical imaging and transcutaneous ultrasound imaging were used to follow up the tumor growth over 2 weeks. For in-vivo technical validation of the new technique, pigs in two groups received either intrabiliary delivery of GFP/HSV-TK/plasmid using a needle-integrated balloon catheter flowed by RFH enhancement (n = 6) or gene delivery only (n = 6). GFP signal in bile duct walls were quantified by optical imaging.The non- parametric Mann-Whitney U test was used for statistical comparison of variables. MTS assay demonstrated the lowest cell proliferation in combination therapy compared with three control groups (24.0 ± 5.3% vs 41.9 ± 6.4% vs 72.0 ± 9.0% vs 100%, p<0.001). GFP optical imaging confirmed that GFP/HSV-TK gene expression peaked at day 2 after gene transfection. Bioluminescent optical imaging demonstrated the decreased bioluminescence signals in tumors of combination therapy, compared with other control groups (0.71 ± 0.16 vs 1.46 ± 0.21 vs 2.10 ± 0.27 vs 2.36 ± 0.28, p<0.001). Ultrasound imaging showed the smallest tumor volumes of the combination therapy group, compared with other groups (0.90 ± 0.21 VS 1.61 ± 0.21 VS 2.22 ± 0.25 VS 2.50 ± 0.30, p<0.001). optical imaging confirmed higher GFP expression in the bile ducts with RFH enhancement (signal to noise ratio: 1.28 ± 0.61 VS 0.49 ± 0.31, P<0.05). It is feasible to use intratumoral RFH to enhance GFP/HSV-TK/plasmid gene expression and HSV-TK/GCV gene therapy of cholangiocarcinomas.This concept may pave a new avenue for managing pancreatobiliary malignancies.(supported by an NIH RO1EBO12467)